ELAN · Elanco Animal Health Inc · Metrics
Market Cap
$11.98B
Shares
499.62M
ELAN metrics
73 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$23.55
Market cap
$11.98B
Price action
20 metricsPrice change (1W)
+0.3%
Price change (30D)
+7.6%
Price change (3M)
-2.2%
Price change (6M)
+1.3%
Price change (YTD)
+5.9%
Price change (1Y)
+25.8%
Trailing year
Price change (5Y)
-29.3%
52-week high
$26.84
52-week low
$18.33
Change from 52-week high
-10.7%
Change from 52-week low
+30.8%
Annualized volatility
42.4%
Annualized volatility (3M)
42.7%
Beta
1.4
RSI (14D)
47.3
Price vs SMA 50
-2.7%
Price vs SMA 200
+0.9%
Avg volume (3M)
5.97M
Relative volume
0.7
Average dollar volume
$144.77M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
499.62M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.4×
reciprocal yield 41.9%
P / book
1.8
reciprocal yield 55.0%
FCF yield
3.2%
TTM · current market cap
Buyback yield
—
P / FCF
31.6
reciprocal yield 3.2%
P / operating cash flow
19.4
reciprocal yield 5.2%
Earnings yield
-1.7%
Historical valuation
8 metricsP / E historical average (3Y)
79.1×
reciprocal yield 1.3%
P / E historical average (5Y)
79.1×
reciprocal yield 1.3%
EV / revenue historical average (3Y)
2.8×
reciprocal yield 35.2%
EV / revenue historical average (5Y)
3.0×
reciprocal yield 33.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-05
Profitability
9 metricsGross margin
55.4%
Operating margin
—
Trailing 12 months
Net margin
-4.0%
Gross profit (TTM)
$2.78B
Operating profit (TTM)
—
Net income (TTM)
−$199.00M
Trailing 12 months
Diluted EPS (TTM)
$-0.40
FCF margin
7.5%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+10.2%
Year over year
Net income growth YoY
+390.9%
Revenue (TTM)
$5.02B
Trailing 12 months
EPS growth YoY
+450.0%
Shares change YoY
+1.2%
Year over year · more shares
Revenue CAGR (3Y)
+2.2%
Revenue CAGR (5Y)
+7.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+0.4%
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-3.0%
Return on assets
-1.5%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
—
Free cash flow (TTM)
$379.00M
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$530.00M
Total assets
$13.56B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$617.00M
Capital expenditures (TTM)
$238.00M
R&D (TTM)
$371.00M
SG&A (TTM)
$1.52B
Stock compensation (TTM)
$74.00M
R&D / revenue
7.4%
Stock compensation / revenue
1.5%
Ownership (13F)
3 metrics13F filers
522
13F filer change QoQ
+2
Institutional ownership
113.5%
Short interest
3 metricsShort interest
5.9%
Latest settlement · 2.5 days to cover
Days to cover
2.5d
Short-squeeze score
55 / 100
Insider activity
2 metricsNet insider buying (90D)
$1.47M
Insider-sentiment score
90 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1739104
CUSIP
28414H103
13F (30d)
245 filings
243 filers
Visit website
Investor relations